AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
ciclopirox 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antimycotics, pyridone derivatives | 636 | 29342-05-0 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
The mechanism of action of ciclopirox has been investigated using various in vitro and in vivo infection models. One in vitro study suggested that ciclopirox acts by chelation of polyvalent cations (Fe+3 or Al+3) resulting in the inhibition of the metal-dependent enzymes that are responsible for the degradation of peroxides within the fungal cell. The clinical significance of this observation is not known.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,ITK,JAK1,JAK2,MAP3K21,MAP3K7,MAPK12,MAPK7,MAPK9,MAPKAPK2,MARK4,MET,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIK3CD,PIM2,PLK1,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ULK2 | 51 | |||
| kinase-selectivity-class | AXL,EIF2AK3,GRK2 | 3 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 30, 1982 | FDA | MEDIMETRIKS PHARMS |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| PRIDE syndrome | 31.50 | 21.56 | 4 | 2531 | 16 | 90625896 |
| Dry skin | 30.93 | 21.56 | 23 | 2512 | 88050 | 90537862 |
| Dermatitis atopic | 23.55 | 21.56 | 12 | 2523 | 23460 | 90602452 |
| Psoriasis | 22.43 | 21.56 | 24 | 2511 | 147730 | 90478182 |
| Fall | 21.72 | 21.56 | 44 | 2491 | 481766 | 90144146 |
| Chronic cutaneous lupus erythematosus | 21.68 | 21.56 | 5 | 2530 | 861 | 90625051 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Device dislocation | 154.87 | 23.97 | 39 | 1463 | 7792 | 42612041 |
| Device malfunction | 141.87 | 23.97 | 40 | 1462 | 12287 | 42607546 |
| Drug ineffective | 84.30 | 23.97 | 106 | 1396 | 630091 | 41989742 |
| Angioplasty | 29.79 | 23.97 | 7 | 1495 | 1037 | 42618796 |
| Nail injury | 28.23 | 23.97 | 4 | 1498 | 32 | 42619801 |
| Administration site dermatitis | 27.76 | 23.97 | 3 | 1499 | 0 | 42619833 |
| Dermatitis atopic | 24.95 | 23.97 | 11 | 1491 | 12393 | 42607440 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Device malfunction | 153.38 | 20.21 | 48 | 3153 | 25510 | 110560588 |
| Device dislocation | 147.19 | 20.21 | 49 | 3152 | 31655 | 110554443 |
| Drug ineffective | 63.96 | 20.21 | 137 | 3064 | 1520403 | 109065695 |
| Dermatitis atopic | 33.97 | 20.21 | 16 | 3185 | 25525 | 110560573 |
| PRIDE syndrome | 29.74 | 20.21 | 4 | 3197 | 26 | 110586072 |
| Administration site dermatitis | 28.35 | 20.21 | 3 | 3198 | 0 | 110586098 |
| Dry skin | 22.23 | 20.21 | 21 | 3180 | 107632 | 110478466 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | D01AE14 | DERMATOLOGICALS ANTIFUNGALS FOR DERMATOLOGICAL USE ANTIFUNGALS FOR TOPICAL USE Other antifungals for topical use |
| ATC | G01AX12 | GENITO URINARY SYSTEM AND SEX HORMONES GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS Other antiinfectives and antiseptics |
| FDA MoA | N0000000150 | Protein Synthesis Inhibitors |
| FDA PE | N0000008577 | Decreased DNA Replication |
| FDA PE | N0000008841 | Decreased Protein Synthesis |
| FDA PE | N0000008853 | Decreased RNA Replication |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000935 | Antifungal Agents |
| CHEBI has role | CHEBI:33282 | antibacterial agent |
| CHEBI has role | CHEBI:59010 | antiseborrheic |
| CHEBI has role | CHEBI:173084 | ferroptosis inhibitor |
| CHEBI has role | CHEBI:176497 | geroprotector |
| CHEBI has role | CHEBI:50177 | dermatologic drug |
Related Drugs by ATC class:
D01AE Other antifungals for topical use 23 drugs
G01AX Other antiinfectives and antiseptics 10 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Tinea pedis | indication | 6020002 | DOID:12403 |
| Candidiasis of skin | indication | 49883006 | |
| Seborrheic dermatitis | indication | 50563003 | DOID:8741 |
| Pityriasis versicolor | indication | 56454009 | DOID:9060 |
| Tinea corporis | indication | 84849002 | |
| Pityriasis simplex | indication | 200767005 | |
| Tinea cruris | indication | 399029005 | |
| Onychomycosis due to dermatophyte | indication | 402134005 | |
| Skin irritation | contraindication | 367466007 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 6.74 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Poly [ADP-ribose] polymerase 1 | Enzyme | INHIBITOR | IC50 | 6.80 | IUPHAR | ||||
| Deoxyhypusine hydroxylase | Enzyme | IC50 | 5.30 | CHEMBL | |||||
| Lysine-specific demethylase 4B | Enzyme | IC50 | 5.42 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019678 | VUID |
| N0000147770 | NUI |
| D01364 | KEGG_DRUG |
| 41621-49-2 | SECONDARY_CAS_RN |
| 21090 | RXNORM |
| C0055711 | UMLSCUI |
| CHEBI:453011 | CHEBI |
| CHEMBL1413 | ChEMBL_ID |
| DB01188 | DRUGBANK_ID |
| CHEMBL242580 | ChEMBL_ID |
| D000077768 | MESH_DESCRIPTOR_UI |
| 2749 | PUBCHEM_CID |
| 11349 | IUPHAR_LIGAND_ID |
| 3101 | INN_ID |
| 19W019ZDRJ | UNII |
| 16731 | MMSL |
| 207997 | MMSL |
| 44089 | MMSL |
| 4445 | MMSL |
| 8601 | MMSL |
| 002925 | NDDF |
| 004961 | NDDF |
| 372854000 | SNOMEDCT_US |
| 70169009 | SNOMEDCT_US |
| 79736009 | SNOMEDCT_US |
| B4O | PDB_CHEM_ID |
| 4018464 | VANDF |
| 4019678 | VANDF |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Ciclopirox | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0168-0314 | LOTION | 7.70 mg | TOPICAL | ANDA | 16 sections |
| Ciclopirox | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0168-0407 | GEL | 7.70 mg | TOPICAL | ANDA | 19 sections |
| CICLOPIROX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0574-2061 | GEL | 7.70 mg | TOPICAL | ANDA | 19 sections |
| Ciclopirox | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-2159 | SHAMPOO | 10 mg | TOPICAL | ANDA | 16 sections |
| Ciclopirox Olamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0713-0638 | CREAM | 7.70 mg | TOPICAL | ANDA | 15 sections |
| Ciclopirox | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-475 | SOLUTION | 71.30 mg | TOPICAL | ANDA | 24 sections |
| CICLOPIROX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21922-053 | SOLUTION | 80 mg | TOPICAL | ANDA | 17 sections |
| CICLOPIROX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21922-053 | SOLUTION | 80 mg | TOPICAL | ANDA | 17 sections |
| CICLOPIROX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21922-105 | SHAMPOO | 1 g | TOPICAL | ANDA | 27 sections |
| Ciclopirox | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42192-715 | SOLUTION | 80 mg | TOPICAL | ANDA | 10 sections |
| Ciclodan | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43538-500 | SOLUTION | 2.28 g | TOPICAL | ANDA | 24 sections |
| Ciclopirox olamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 45802-138 | CREAM | 7.70 mg | TOPICAL | ANDA | 16 sections |
| Ciclopirox | HUMAN PRESCRIPTION DRUG LABEL | 1 | 45802-141 | SOLUTION | 80 mg | TOPICAL | ANDA | 23 sections |
| Ciclopirox | HUMAN PRESCRIPTION DRUG LABEL | 1 | 45802-141 | SOLUTION | 80 mg | TOPICAL | ANDA | 23 sections |
| Ciclopirox Olamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 45802-400 | SUSPENSION | 7.70 mg | TOPICAL | ANDA | 17 sections |
| Ciclopirox Olamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 45802-400 | SUSPENSION | 7.70 mg | TOPICAL | ANDA | 17 sections |
| Ciclopirox | HUMAN PRESCRIPTION DRUG LABEL | 1 | 45802-401 | SHAMPOO | 1 g | TOPICAL | ANDA | 24 sections |
| Ciclopirox | HUMAN PRESCRIPTION DRUG LABEL | 1 | 45802-401 | SHAMPOO | 1 g | TOPICAL | ANDA | 24 sections |
| Ciclopirox | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-6562 | SOLUTION | 80 mg | TOPICAL | ANDA | 10 sections |
| Ciclopirox | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-6562 | SOLUTION | 80 mg | TOPICAL | ANDA | 10 sections |
| Ciclopirox | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50383-419 | SOLUTION | 71.30 mg | TOPICAL | ANDA | 24 sections |
| Ciclopirox Olamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51672-1318 | CREAM | 7.70 mg | TOPICAL | ANDA | 20 sections |
| Ciclopirox | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51672-1351 | SHAMPOO | 10 mg | TOPICAL | ANDA | 27 sections |
| Ciclopirox | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51672-5302 | SOLUTION | 80 mg | TOPICAL | ANDA | 24 sections |
| Ciclopirox | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52565-032 | SHAMPOO | 10 mg | TOPICAL | ANDA | 27 sections |
| Ciclopirox Olamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53002-9450 | CREAM | 7.70 mg | TOPICAL | ANDA | 19 sections |
| Ciclopirox Olamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-5270 | CREAM | 7.70 mg | TOPICAL | ANDA | 17 sections |
| Ciclopirox | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-6064 | SOLUTION | 80 mg | TOPICAL | ANDA | 13 sections |
| Ciclopirox | HUMAN PRESCRIPTION DRUG LABEL | 1 | 61360-1351 | SHAMPOO | 10 mg | TOPICAL | ANDA | 24 sections |
| CICLOPIROX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 61748-200 | SOLUTION | 80 mg | TOPICAL | ANDA | 26 sections |